Non-invasive tests of non-alcoholic fatty liver disease

来源 :中华医学杂志英文版 | 被引量 : 0次 | 上传用户:ajunyx
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
For the detection of steatosis, quantitative ultrasound imaging techniques have achieved great progress in past years. Magnetic resonance imaging proton density fat fraction is currently the most accurate test to detect hepatic steatosis. Some blood biomarkers correlate with non-alcoholic steatohepatitis, but the accuracy is modest. Regarding liver fibrosis, liver stiffness measurement by transient elastography (TE) has high accuracy and is widely used across the world. Magnetic resonance elastography is marginally better than TE but is limited by its cost and availability. Several blood biomarkers of fibrosis have been used in clinical trials and hold promise for selecting patients for treatment and monitoring treatment response. This article reviews new developments in the non-invasive assessment of non-alcoholic fatty liver disease (NAFLD). Accumulating evidence suggests that various non-invasive tests can be used to diagnose NAFLD, assess its severity, and predict the prognosis. Further studies are needed to determine the role of the tests as monitoring tools. We cannot overemphasize the importance of context in selecting appropriate tests.“,”For the detection of steatosis, quantitative ultrasound imaging techniques have achieved great progress in past years. Magnetic resonance imaging proton density fat fraction is currently the most accurate test to detect hepatic steatosis. Some blood biomarkers correlate with non-alcoholic steatohepatitis, but the accuracy is modest. Regarding liver fibrosis, liver stiffness measurement by transient elastography (TE) has high accuracy and is widely used across the world. Magnetic resonance elastography is marginally better than TE but is limited by its cost and availability. Several blood biomarkers of fibrosis have been used in clinical trials and hold promise for selecting patients for treatment and monitoring treatment response. This article reviews new developments in the non-invasive assessment of non-alcoholic fatty liver disease (NAFLD). Accumulating evidence suggests that various non-invasive tests can be used to diagnose NAFLD, assess its severity, and predict the prognosis. Further studies are needed to determine the role of the tests as monitoring tools. We cannot overemphasize the importance of context in selecting appropriate tests.
其他文献
目的 探讨年度考核中应用客观结构化考核(objective structured clinical examination,OSCE)对提升脑血管病住院医师结业考核成绩的作用.方法 回顾性连续纳入2018-2021年首都医科大学附属北京天坛医院参加北京市住院医师规范化培训结业技能考核的脑血管病住院医师,收集其规范化培训第三年的年度考核成绩及结业考核成绩,按照第三年的年度考核成绩分为前1/3组、中1/3组和后1/3组,比较3组年度考核和结业考核成绩变化(结业考核成绩-第三年年度考核成绩)的差异,分析OSCE
期刊
期刊
Metabolic (dysfunction) associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most common cause of chronic liver disease worldwide. Many risk factors contribute to the pathogenesis of MAFLD with metabolic dy
院内卒中是指因其他疾病住院的患者在住院期间发生的急性卒中,其中最常见的类型是缺血性卒中.与社区卒中相比,院内缺血性卒中的危险因素和发病机制更为复杂,除了栓塞、低灌注、高凝状态,医源性因素也是重要的致病原因之一.院内缺血性卒中患者的不良功能预后和死亡率均较社区患者显著增高,研究提示基础疾病较多、围手术期栓塞所致脑梗死范围更大以及再灌注治疗率较低等因素均是预后不良的重要原因.早期识别卒中并快速启动绿色通道是影响院内卒中救治效果的重要因素,也是院内卒中急救体系建设的重点;另外,提高再灌注治疗率也是院内卒中急救体
目的 探讨毛柳苷在缺血性脑损伤后对白介素4诱导蛋白1(interleukin-4 induced protein 1,IL4I1)表达及小胶质细胞极化的影响.方法 38只雄性C57BL/6J小鼠随机分为假手术组(4只)、毛柳苷组(17只)和生理盐水组(17只).通过线栓法制作大脑中动脉缺血再灌注模型(缺血60?min拔栓实现再灌注),再灌注10?min后,毛柳苷组与生理盐水组小鼠分别经尾静脉按照10?mg/kg剂量注射毛柳苷(1?mg/mL)与生理盐水,每天1次,持续28?d.ELISA法检测假手术组及模
期刊
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients ca
期刊
期刊